Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.
Sham Mailankody, MBBS
Advertisement
Articles by Sham Mailankody, MBBS
Sham Mailankody, MBBS, discusses minimal residual disease negativity in multiple myeloma.
Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Advertisement
Latest Updated Articles
Dr. Mailankody on MRD-Negative Status in Multiple MyelomaNovember 23rd 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5